Early Changes of the Standardized Uptake Values (SUV(max)) Predict the Efficacy of Everolimus-Exemestane in Patients with Hormone Receptor-Positive Metastatic Breast Cancer

SIMPLE SUMMARY: The combination of everolimus and exemestane was FDA approved after BOLERO-2 clinical trial results for the treatment of hormone receptor-positive (HR+) human epidermal growth factor receptor 2-negative (HER2−) metastatic breast cancer (HR+ mBC), progressing on a prior therapy with a...

Descripción completa

Detalles Bibliográficos
Autores principales: Sirico, Marianna, Bernocchi, Ottavia, Sobhani, Navid, Giudici, Fabiola, Corona, Silvia P., Vernieri, Claudio, Nichetti, Federico, Cappelletti, Maria Rosa, Milani, Manuela, Strina, Carla, Cervoni, Valeria, Barbieri, Giuseppina, Ziglioli, Nicoletta, Dester, Martina, Bianchi, Giulia Valeria, De Braud, Filippo, Generali, Daniele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7697290/
https://www.ncbi.nlm.nih.gov/pubmed/33182575
http://dx.doi.org/10.3390/cancers12113314

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7697290/
https://www.ncbi.nlm.nih.gov/pubmed/33182575
http://dx.doi.org/10.3390/cancers12113314

Ejemplares similares